الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 150 |  |  |
| | | from | 150 | | |
Abstract
Background: Estrogen dependent cancer is a common type of malignancy which is complicated and involve many co-regulators. Aromatase enzyme, integrin β4 (ITGB4) and histone deacetylase 4 (HDAC4) are strongly related to this type of carcinogenesis. Additionally, estrogen reliant on oxidative stress is highly involved. Aromatase inhibitors are the first line management for such types of cancer, and third generation letrozole (LET) is the most recent and commonly used one. Lately, new approaches in tumor management include supplements that might have antitumor effects are under investigation. Taurine (TAU) is chosen to be combined with LET on Ehrlich ascites carcinoma model for its antioxidant and potential anticancer effects. Method: Sixty Swiss-albino female mice were divided into five groups (n = 12): Control group (Normal), EAC group, LET group, TAU group and LET+TAU group. TAU (150 mg/kg, orally) was given day after day for 14 days along with LET (5 mg/kg, orally). After 14 days, mice were sacrificed, ascetic fluid, blood and liver were isolated immediately. HDAC4, ITGB4 and aromatase enzyme genes expression were estimated in liver, vascular endothelial growth factor (VEGF) content was determined by ELISA method in liver, and some oxidative status biomarkers were measured in blood. Results: Treatment with TAU significantly down regulated hepatic HDAC4, ITGB4 and aromatase genes expression, content of hepatic VEGF and improved the anti-oxidant characteristics in EAC mice. Conclusion: TAU was observed to improve the anticancer characteristics of LET and might have beneficial role as supplement therapy that has potential anticancer activity in estrogen dependent cancer management protocols.